Product image of Metazero (Metoprolol Succinate) supplied by GNH India

Metazero

Active Ingredient:
Metoprolol Succinate
Origin:
EU

Metazero (Metoprolol Succinate)

Metoprolol succinate, the active ingredient in Metazero, is a beta blocker presented as a tablet for oral use. It treats hypertension, angina pectoris, chronic heart failure and is used for post‑myocardial infarction prophylaxis in adults.

GNH India supplies Metazero as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Krka, D.D., Novo Mesto

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Metazero (metoprolol succinate) is a beta‑adrenergic blocker used in cardiovascular disease management.

  • Hypertension: lowers systemic blood pressure and reduces vascular resistance.
  • Angina pectoris: decreases frequency and severity of chest pain episodes.
  • Chronic heart failure: improves functional capacity and reduces hospitalisation risk.
  • Post‑myocardial infarction prophylaxis: lowers the chance of recurrent cardiac events.

How It Works

  • Metoprolol succinate selectively antagonises β1‑adrenergic receptors in cardiac tissue, decreasing heart rate, myocardial contractility and renin release. This results in reduced cardiac output and lower systemic blood pressure, while also diminishing myocardial oxygen demand and stabilising ventricular rhythm after infarction.

Side Effects

Metazero may cause a range of adverse reactions, most of which are dose‑related and reversible.

Common Side Effects

  • Fatigue or tiredness
  • Dizziness or light‑headedness
  • Bradycardia (slow heart rate)
  • Cold extremities
  • Gastrointestinal upset (nausea, abdominal discomfort)
  • Mood changes such as mild depression

Serious or Rare Side Effects

  • Severe bradycardia or heart block
  • Marked hypotension
  • Bronchospasm, especially in patients with asthma or COPD
  • Allergic reactions (rash, angioedema, anaphylaxis)
  • Worsening heart failure symptoms
  • Cardiogenic shock in extreme cases

Precautions & Warnings

Before initiating Metazero, clinicians should assess individual risk factors and monitor patients closely.

  • Blood pressure monitoring: ensure adequate control before dose escalation.
  • Renal impairment: adjust dose in patients with reduced kidney function.
  • Abrupt discontinuation: taper gradually to avoid rebound tachycardia.
  • Respiratory disease: use with caution in asthma or COPD.
  • Diabetes: monitor glucose as beta‑blockade may mask hypoglycaemia.
  • Store at room temperature: keep in the original container, protect from moisture and light.

Avoid Interactions

Metazero can interact with several drug classes; awareness of interaction severity guides clinical decisions.

Major Interactions (Avoid)

  • Combined use with other AV‑node blockers (e.g., verapamil, diltiazem) may cause profound bradycardia.
  • Concomitant clonidine therapy: abrupt withdrawal can precipitate hypertensive crisis.
  • Potent CYP2D6 inhibitors (e.g., quinidine, fluoxetine) increase metoprolol plasma levels.
  • MAO inhibitors: risk of severe hypertension.
  • Insulin or sulfonylureas: beta‑blockade may mask hypoglycaemic symptoms.

Moderate Interactions (Monitor Closely)

  • NSAIDs: may attenuate antihypertensive effect.
  • Diuretics: additive hypotensive effect, monitor electrolytes.
  • Calcium‑channel blockers (e.g., amlodipine): may enhance heart‑rate reduction.
  • Antidiabetic agents: may require dose adjustment.
  • SSRIs or other antidepressants: potential for increased bradycardia.

Frequently Asked Questions

Metazero contains metoprolol succinate, a beta‑blocker prescribed to manage hypertension, relieve angina pectoris, treat chronic heart failure, and reduce the risk of recurrent events after a myocardial infarction. It is used in adult patients when a selective β1‑adrenergic antagonist is indicated.

Metoprolol succinate selectively blocks β1‑adrenergic receptors in the heart, leading to a slower heart rate, reduced contractile force, and lower renin release. These actions decrease cardiac output and systemic blood pressure, lessen myocardial oxygen demand, and help stabilise heart rhythm after an infarction.

The appropriate dose of Metazero is determined by the prescribing clinician based on the individual’s medical condition, response to therapy, and renal function. Dosage may be titrated gradually, and patients should follow the specific instructions provided by their healthcare professional.

Safety data for metoprolol succinate in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their physician.

To request Metazero, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Metazero (metoprolol succinate) is a long‑acting, selective β1‑blocker, offering once‑daily dosing and a smoother plasma‑level profile compared with short‑acting agents like propranolol. Its selectivity reduces bronchial side effects, making it preferable for patients with respiratory concerns, while still providing effective blood‑pressure and heart‑failure control.

Metazero should be stored at room temperature, below 25 °C, in its original packaging. Keep the tablets away from moisture, direct sunlight and excessive heat to maintain potency throughout the shelf‑life.

Metazero is taken orally, usually as a whole tablet swallowed with water. It is typically administered once daily, but the exact schedule and timing (e.g., with or without food) should follow the prescribing clinician’s guidance.

Serious adverse events include severe bradycardia, heart block, marked hypotension, bronchospasm in patients with asthma or COPD, and worsening heart failure. Patients should be monitored for these signs, and therapy should be discontinued promptly if they occur.

Metazero is contraindicated in patients with known hypersensitivity to metoprolol or other beta‑blockers, those with severe bradycardia, second‑ or third‑degree heart block without a pacemaker, cardiogenic shock, or uncontrolled asthma. Clinicians must evaluate each patient’s medical history before prescribing.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Metoprolol Succinate

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT